0 CHECKOUT

Raynauds Disease - Pipeline Review, H2 2015

  • ID: 3502756
  • October 2015
  • 61 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Apricus Biosciences, Inc.
  • Bayer AG
  • MORE

Raynauds Disease - Pipeline Review, H2 2015

Summary

The report ‘Raynauds Disease - Pipeline Review, H2 2015’, provides an overview of the Raynauds Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Raynauds Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Raynauds Disease and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Apricus Biosciences, Inc.
  • Bayer AG
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Raynauds Disease Overview

Therapeutics Development

Pipeline Products for Raynauds Disease - Overview

Pipeline Products for Raynauds Disease - Comparative Analysis

Raynauds Disease - Therapeutics under Development by Companies

Raynauds Disease - Therapeutics under Investigation by Universities/Institutes

Raynauds Disease - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Raynauds Disease - Products under Development by Companies

Raynauds Disease - Products under Investigation by Universities/Institutes

Raynauds Disease - Companies Involved in Therapeutics Development

Allergan Plc

Apricus Biosciences, Inc.

Bayer AG

Human Stem Cells Institute

Raynauds Disease - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

alprostadil - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ELS-140 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

neovasculgen - Drug Profile

Product Description

Mechanism of Action

R&D Progress

onabotulinumtoxin A - Drug Profile

Product Description

Mechanism of Action

R&D Progress

riociguat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Alpha 2 Adrenergic Receptor for Raynauds Disease - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Raynauds Disease - Recent Pipeline Updates

Raynauds Disease - Dormant Projects

Raynauds Disease - Discontinued Products

Raynauds Disease - Product Development Milestones

Featured News & Press Releases

Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference

Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May

Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa

Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon

Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa

Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum

May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon

May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon

Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa

Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Raynauds Disease, H2 2015

Number of Products under Development for Raynauds Disease - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Raynauds Disease - Pipeline by Allergan Plc, H2 2015

Raynauds Disease - Pipeline by Apricus Biosciences, Inc., H2 2015

Raynauds Disease - Pipeline by Bayer AG, H2 2015

Raynauds Disease - Pipeline by Human Stem Cells Institute, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Raynauds Disease Therapeutics - Recent Pipeline Updates, H2 2015

Raynauds Disease - Dormant Projects, H2 2015

Raynauds Disease - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Raynauds Disease, H2 2015

Number of Products under Development for Raynauds Disease - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Allergan Plc
Apricus Biosciences, Inc.
Bayer AG
Human Stem Cells Institute

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Cytori Therapeutics, Inc.
  • Pfizer Inc.
  • Medtronic, Inc.
  • St. Jude Medical, Inc.
  • Novo Nordisk A/S
  • Lumedx